HR 661, the MIRACLE Medical Technology Act of 2025, establishes a formal US-Israel program to coordinate collaboration on developing and delivering healthcare products and services. It directs the Secretary of Health and Human Services to create joint initiatives - including shared research on medical devices and pharmaceuticals, regulatory alignment (like FDA-Israel regulatory data sharing), innovation hubs for startups, and telemedicine infrastructure - leveraging $8 million annually from 2026-2030. The bill directly affects US health agencies (HHS, FDA), Israeli health authorities, and medical technology companies in both countries. Key mechanisms include creating a US-Israel Health Care Collaboration Center, promoting joint manufacturing facilities for biological products, and standardizing data sharing for research. This focuses on concrete policy changes to enhance bilateral medical innovation and healthcare delivery.
S 1609, "Ellie’s Law," authorizes $10 million annually (2026-2030) for the National Institute of Neurological Disorders and Stroke to fund comprehensive research on unruptured brain aneurysms. The bill directly affects patients - particularly women, African Americans, and Hispanic individuals who face higher rupture risks - and medical researchers studying prevention and treatment. Key provisions require the research to diversify study populations by age, sex, and race, while ensuring new funds supplement, not replace, existing brain aneurysm research funding. This addresses a critical gap, as current federal spending averages just $2.94 per patient annually despite the condition affecting 6.8 million people and costing $2 billion yearly in direct medical expenses.
HR 2040, the NEWBORN Act, creates federal grants for local health departments to run infant mortality pilot programs in the 50 highest-risk counties. The $10 million annual funding (2025-2029) requires grantees to develop community-specific plans addressing causes like preterm birth, maternal complications, and infant injuries. Programs must include outreach to at-risk mothers, standardized services (postpartum care, smoking cessation, nutrition counseling), rural health initiatives, and public education campaigns. Grantees must report annually on program outcomes, with funds limited to 10% for evaluation. The bill directly affects communities with high infant mortality rates and at-risk mothers and infants through these targeted, evidence-based interventions.
HR 6897, the Thyroid Disease CARE Act of 2025, directs the U.S. Department of Health and Human Services to fund research and public awareness efforts focused on thyroid disease. It authorizes $30 million annually (2026-2030) to study disparities in diagnosis, treatment, and outcomes - particularly for women and underserved groups like racial minorities, people with disabilities, and those with limited insurance - while developing new diagnostic tools and treatments. The bill also allocates $3 million yearly for a public campaign to educate patients about symptoms, treatment options, and screening, especially during pregnancy, and to train healthcare providers on equitable care. This legislation affects patients with thyroid conditions (including nodules and cancer), healthcare systems, and providers, without altering insurance coverage or creating new benefits.
This bill (S 2529) clarifies the process for switching prescription drugs to over-the-counter (OTC) status. It requires the FDA to hold meetings with drug manufacturers to develop application plans, issue new guidance within 18 months on evidence standards (including how to use medical literature and demonstrate consumer understanding), and create a public stakeholder engagement plan. The bill directly affects drug manufacturers seeking to switch products and the FDA’s review process. Key provisions define "full" (same use conditions) and "partial" (limited conditions) switches and set clear expectations for supporting evidence, aiming to make the approval process more predictable.
The EASE Act (S 1248) creates a new Medicare and Medicaid model to improve access to specialty health care for beneficiaries in rural or underserved areas. It requires the Centers for Medicare & Medicaid Services to partner with nonprofit provider networks (comprising at least 50 rural clinics or health centers) to deliver specialty care via telehealth and remote technologies, coordinated with primary care providers. Eligible individuals include Medicare Part B beneficiaries or Medicaid/CHIP enrollees living in designated rural or underserved areas. The model mandates that selected provider networks must have proven experience serving rural communities and the capacity to track health data for evaluation.
This bill allows seniors to use tax-free health savings account (HSA) funds for qualified home care services. It defines "qualified home care" as contracts providing three or more specific personal care services (like assistance with bathing, dressing, or medication) from state-licensed providers. The policy change directly affects seniors needing home care who use HSAs, excluding family-provided care and requiring state licensing compliance. A public awareness campaign will also inform seniors about eligible services.
This bill, the Health Marketplace and Savings Accounts for All Act, makes significant changes to Health Savings Accounts (HSAs) and creates a new framework for health marketplace pools. It increases HSA contribution limits, allows rollovers to children or parents, and expands qualifying expenses to include vitamins, dietary supplements, gym memberships, and wearable fitness trackers. The bill establishes health marketplace pools that can function as employers to offer group health plans, with requirements to prevent health status discrimination in membership and enrollment. These pools can offer coverage that includes only drug benefits as a primary offering, while maintaining consistent enrollment rules that don't consider health status. The legislation aims to increase flexibility and accessibility of health savings options while creating new structures for health coverage.
S 3271, the In-Home CARE Act, establishes a federal grant program to support family caregivers of individuals with chronic health conditions, disabilities, or functional limitations who receive care at home. The bill authorizes 3-year competitive grants for eligible organizations (like local agencies, healthcare entities, or nonprofits) to provide home visiting services that assess caregivers' needs, offer evidence-based education (e.g., on medication management, fall prevention, or mental health support), and connect caregivers to resources like respite care or home modifications. These grants require grantees to conduct initial assessments, deliver targeted training, and coordinate with existing programs like the National Family Caregiver Support Program. The goal is to help caregivers better support their loved ones at home, potentially reducing hospitalizations and institutional care while improving quality of life for both caregivers and care recipients.
HR 4837, the Written Informed Consent Act, requires the Veterans Health Administration (VHA) to update its existing directive on informed consent to include additional medication classes. Specifically, it mandates that written informed consent must be obtained before prescribing antipsychotics, stimulants, antidepressants, anti-anxiety medications (anxiolytics), and narcotics (opioids) to veterans. This expansion directly affects veterans receiving these medications through the VA system, ensuring they are informed about specific treatment risks and alternatives. The key mechanism is amending VHA Directive 1005 to broaden its application beyond long-term opioid therapy to cover the newly listed medication types.
